Patent intelligence · US
US 12247037
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders
1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopres…
Patent details — US 12247037
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 11, 2025
- Expiration
- Mar 6, 2045
- Applicant
- Neumora Therapeutics, Inc.
- Claims
- 29
- CPC classes
- A61P, A61P25/18, A61P25/22, A61P25/24
Quick answer
US 12247037 (1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Neumora Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61P, A61P25/18, A61P25/22, A61P25/24
More from Neumora Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12371414
Methods of treating neurological disorders
granted -
US 12171758
Crystalline salt forms of kappa opioid receptor antagonist and products and methods related thereto
granted -
US 12152038
Vasopressin receptor antagonists and products and methods related thereto
granted -
US 11993580
Methods of treating neurological disorders
granted -
US 11858943
Vasopressin receptor antagonists and products and methods related thereto
granted
Frequently asked questions
What is US patent 12247037?
US 12247037 (1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders) is held by Neumora Therapeutics, Inc.. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12247037?
Neumora Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 12247037 expire?
Our index shows an expiration date of Mar 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.